World Health Organization. WHO bacterial priority pathogens list. 2024. https://iris.who.int/server/api/core/bitstreams/1a41ef7e-dd24-4ce6-a9a6-1573562e7f37/content. Accessed 09 Jul 2026.

Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024;https://doi.org/10.1093/cid/ciae403.

Carcione D, Siracusa C, Sulejmani A, et al. Old and new beta-lactamase inhibitors: molecular structure, mechanism of action, and clinical use. Antibiotics (Basel). 2021;10(8):995.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sader HS, Castanheira M, Huband M, et al. WCK 5222 (cefepime-zidebactam) antimicrobial activity against clinical isolates of Gram-negative bacteria collected worldwide in 2015. Antimicrob Agents Chemother. 2015;61(5):e00072-17.

Article  Google Scholar 

Wockhardt. Indian drug regulator grants marketing authorization to Wockhardt's breakthrough antibiotic, ZAYNICH® (zidebactam/cefepime), for treatment of complicated urinary tract infections including pyelonephritis with concurrent Gram-negative bacteremia [media release]. 28 May 2026. https://www.wockhardt.com/wp-content/uploads/2026/05/pr-zaynich-28-may-2026.pdf.

Wockhardt. Wockhardt receives U.S. FDA approval for ZAYNICH™ (cefepime and zidebactam), a novel intravenous antibiotic for the treatment of adult patients with complicated urinary tract infection including pyelonephritis [media release]. 30 May 2026. https://www.wockhardt.com/wp-content/uploads/2026/05/wockhardt-zaynich-fda-approval-press-release.pdf.

US FDA. ZAYNICH (cefepime and zidebactam) for injection, for intravenous use: US prescribing information 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220787Orig1s000lbl.pdf. Accessed 09 Jul 2026.

US FDA. Zaynich (cefepime and zidebactam): NDA approval. 2026. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220787Orig1s000ltr.pdf. Accessed 09 Jul 2026.

Wockhardt. Wockhardt files Marketing Authorisation Application for WCK 5222 with European Medicines Agency [media release]. 07 Jan 2026. https://www.wockhardt.com/wp-content/uploads/2026/01/ema-press-release.pdf.

Bulfoni M, Tascini C, Grandesso S, et al. In vitro activity of cefepime/enmetazobactam and cefepime/zidebactam against OXA-48-producing Klebsiella pneumoniae clinical strains. New Microbiol. 2025;48(4):322–6.

PubMed  Google Scholar 

Rezzoug I, Ouacel K, Droit T, et al. Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales: an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol. J Antimicrob Chemother. 2025;80(12):3297–305.

Article  CAS  PubMed  Google Scholar 

Bakthavatchalam YD, Shankar C, Jeyaraj C, et al. In vitro activity of zidebactam/cefepime (WCK 5222), a β-lactam enhancer/ β-lactam combination against carbapenem- and colistin-resistant Klebsiella pneumoniae isolates. Diagn Microbiol Infect Dis. 2025;111(1):116561.

Article  CAS  PubMed  Google Scholar 

Blanco-Martín T, López-Hernández I, Aracil B, et al. Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales. Antimicrob Agents Chemother. 2024;68(11):e0092424.

Article  PubMed  PubMed Central  Google Scholar 

Le Terrier C, Freire S, Nordmann P, et al. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives? Eur J Clin Microbiol Infect Dis. 2024;43(2):339–54.

Article  CAS  PubMed  Google Scholar 

Le Terrier C, Nordmann P, Sadek M, et al. In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates. J Antimicrob Chemother. 2023;78(5):1191–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sader HS, Mendes RE, Duncan LR, et al. Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19). J Antimicrob Chemother. 2018;77(10):2642–9.

Article  Google Scholar 

Bhagwat SS, Legakis NJ, Skalidis T, et al. In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals. Diagn Microbiol Infect Dis. 2021;100(3):115327.

Article  CAS  PubMed  Google Scholar 

Bhagwat SS, Hariharan P, Joshi PR, et al. Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3. J Antimicrob Chemother. 2020;75(12):3563–7.

Article  CAS  PubMed  Google Scholar 

Avery LM, Mullane EM, Nicolau DP. Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: expanding the zone of hope. Int J Antimicrob Agents. 2020;55(105863):1–6.

Google Scholar 

Lasko MJ, Abdelraouf K, Nicolau DP. Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model. J Antimicrob Chemother. 2021;76(9):2310–6.

Article  CAS  PubMed  Google Scholar 

Rodvold KA, Gotfried MH, Chugh R, et al. Plasma and intrapulmonary concentrations of cefepime and zidebactam following intravenous administration of WCK 5222 to healthy adult subjects. Antimicrob Agents Chemother. 2018;62(8):e00682-18.

Article  PubMed  PubMed Central  Google Scholar 

Preston RA, Mamikonyan G, DeGraff S, et al. Single-center evaluation of the pharmacokinetics of WCK 5222 (cefepime-zidebactam combination) in subjects with renal impairment. Antimicrob Agents Chemother. 2019;63(1):e01484-18.

Article  PubMed  Google Scholar 

Genov P, Mladenov B, Slaitas D, et al. Efficacy of β-lactam enhancer based zidebactam-cefepime combination (WCK 5222) versus meropenem in adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) in a global, randomized, double-blind, phase 3 trial [abstract P-1209]. Open Forum Infect Dis. 2026;13(Suppl 1):S793.

Google Scholar 

Wockhardt. Zaynich® (zidebactam/cefepime, WCK 5222) achieves over 97% efficacy in clinical study for serious infections caused by meropenem-resistant Gram-negative pathogens [media release]. 13 Jan 2025. https://www.wockhardt.com/wp-content/uploads/2025/01/zaynich-pr-13-jan-2025.pdf.

Dubey D, Swaminathan S, Wanve B, et al. Real-world experience with compassionate use of zidebactam/cefepime (ZID/FEP) in patients with Gram-negative bacterial infections lacking safe & effective treatment options [poster P4917]. In: ESCMID Global 2026, Munich, Germany.